1. Difference between the Abilities of Human Fcγ Receptor-Expressing CV-1 Cells To Neutralize American and Asian Genotypes of Dengue Virus 2▿
- Author
-
Zhihua Kou, W. W. I. S. Rodrigo, Xia Jin, Robert C. Rose, D. C. Alcena, G. Comach, Jacob J. Schlesinger, Tadeusz J. Kochel, and Kevin R. Porter
- Subjects
Microbiology (medical) ,Serotype ,Genotype ,Clinical Biochemistry ,Immunology ,Virulence ,Viral Plaque Assay ,Biology ,Dengue virus ,Cross Reactions ,medicine.disease_cause ,Antibodies, Viral ,Dengue fever ,Cell Line ,Plaque reduction neutralization test ,Blood serum ,Neutralization Tests ,medicine ,Immunology and Allergy ,Animals ,Humans ,Receptors, IgG ,Dengue Virus ,medicine.disease ,Vaccine Research ,Virology ,Titer - Abstract
Sera from patients involved in a Peruvian outbreak of dengue virus serotype 1 infection cross-neutralized the American genotype of dengue virus serotype 2 up to 100-fold more efficiently than they did the virulent Asian genotype of dengue virus serotype 2, as determined by a plaque reduction neutralization test (PRNT) with CV-1 fibroblasts modified to express human Fcγ receptor CD32. The concordant preferential immune enhancement of the Asian genotype of dengue virus serotype 2 in human monocytes suggests that such a modification might strengthen the correlation between the PRNT titer and protection.
- Published
- 2008